Current clinical management of CIDP with immunoglobulins in France: An expert opinion.
CIDP
Efficacy criteria
IVIg
MCIDs
Maintenance
Treatment
Journal
Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
13
09
2022
revised:
05
01
2023
accepted:
13
03
2023
medline:
13
10
2023
pubmed:
6
4
2023
entrez:
5
4
2023
Statut:
ppublish
Résumé
Treatment strategies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) must be adapted on a case-to-case basis. Validated and reproducible tools for monitoring treatment response are required at diagnosis, when initiating treatment and throughout follow-up. A task force of French neurologists, experts in neuromuscular disease reference centers, was assembled to provide expert advice on the management of typical CIDP with intravenous immunoglobulins (Ig), and to harmonize treatment practices in public and private hospitals. The task force also referred to the practical experience of treating CIDP with Ig at the diagnostic, induction and follow-up stages, including the assessment and management of Ig dependence, and following the recommendations of the French health agency.
Identifiants
pubmed: 37019741
pii: S0035-3787(23)00892-5
doi: 10.1016/j.neurol.2023.03.010
pii:
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Practice Guideline
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
914-922Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.